August 26, 2021 5:07pm

The Biostage (BSTG) Chronicles: Thursday 3,137 share traded (+$0.39 to $2.60, after Wednesday’s 18,710 shares traded (+$0.16 to $2.21), Tuesday’s 15,777 shares traded to prop the $2.05 (+$0.16) share price following Monday’s 38,354 shares (+$0.68 to $1.89) traded following months of 100 to 1,100 daily trading volume. Is it all about exercising $2.00 warrants from multiple private placements to raise any cash for a clinical trial (with an IND aged by 1.5 years) that never began?

  • Being able to trade a stock doesn't mean it is worth the share price; an equity that has NO clinical trial after an approved 1.5-year-old IND.

Pre-open indications: 4 MISS and 5 HITs

My comments try to distinguish the temporary from real pricing digression or progress with a 360-degree view.

Who else is tracking a broad representative index of cell and gene therapy equities – the facts are supported by real numbers?

The Dow closed DOWN -192.38 points (-0.54%); the S&P closed DOWN -26.19 points (-0.58%) while the Nasdaq closed DOWN -95.05 points (-0.64%)

 

Henry’omics:

The Dow, S&P 500 and Nasdaq fell from record highs on Thursday as investors await more details on the Fed’s plan to pull back on monetary stimulus.

  • A senior Fed official said a policy change is due: the Dallas Federal Reserve President Robert Kaplan's commented his concerns over inflation and risk-taking as he wants to see the Fed announce next month that it will begin to scale back on bond purchases.

Traders were also eying new developments in Afghanistan, which added to the risk-off sentiment. At least 11 U.S. Marines and one Navy medic were killed after two explosions went off outside the Kabul airport Thursday. <Associated Press>

  • The president and his “advisors” are complicit in these non-protective actions for our troops.

 

Data Docket: Weekly initial jobless claims came in at 353,000, the Labor Department reported, a slight increase from the prior week’s 349,000 and more than economists expected.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Thursday opened positive at 19/12, 3 flats and 1 acquired, flipped negative at the mid-day at 14/18, 2 flats and 1 acquired, ending with a negative close of 9/23, 2 flat and 1 acquired;

RegMed Investors’ (RMi) pre-open: “low volume and percentage moves to the upside within another record high. Volatility sketches a contradictory picture of the short-term after extending a winning streak to five sessions on the S&P 500 and Nasdaq.” … https://www.regmedinvestors.com/articles/12067

 

The Biostage (BSTG) Chronicles: “Facts from filed 10-Q” … https://www.regmedinvestors.com/articles/12055

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

  • Net Income: 3 and Net losses: 23

 

Key Metrics:

  • Sector volume was LOW with 3 of the 9-upside having higher than the 3-month average volume with very LOW volume of 2 of 23-downside having higher than the 3-month average volume;
  • Wednesday’s percentage (%) of the 9-upside were +0.07% (MDXG) to +17.65% (BSTG) while the 23-downside -0.18% (RARE) to -4.65% (CLBS);

 

The Biostage (BSTG) Chronicles: Thursday traded 3,137 shares after Wednesday traded 18,472 shares traded (+$0.16 to $2.21), Tuesday closed up +$0.28 with 10,590 shares trade after Monday’s +$0.68 with 38,354 shares traded following Friday’s -$0.07 with 570 shares traded and last Thursday’s flat at with 50 shares traded.

  • Today is just another fact, how the share trades with the “push/promote” - another typical example,
  • WHAT is BSTG’s value proposition, after all the share price pumping?
  • WHERE is the SEC?

 

Pre-open Indications: 5 HITs < Pluristem (PSTI +$0.04); SELL:  Sage Therapeutics (SAGE -$0.67), Voyager Therapeutics (VYGR -$0.09), CRISPR Therapeutics (CRSP -$3.90), Editas Medicine (EDIT -$1.72)>   4 MISS < Maintaining SELL: Biostage (BSTG +$0.39), SELL: BioLife Solutions (BLFS+-$0.96), BUY:  Ionis Pharmaceuticals (IONS -$0.64), Intellia therapeutics (NTLA -$3.99)

 

There are clear winners and losers

Jumping with share pricing momentum:

  • BioLife Solutions (BLFS), Chinook Therapeutics (KDNY), Biostage (BSTG) – pumped, Precigen (PGEN), Pluristem (PSTI) to name 5 of the 9 inclining of the 35 covered

Hammered in today’s market:

  • Intellia Therapeutics (NTLA), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), Editas Medicine (EDIT), Alnylam Pharmaceuticals (ALNY) to name 5 of the 23 declining of the 35 covered

 

Thursday’s (9 of 9) incliners:

  • BioLife Solutions (BLFS +$0.96 after Wednesday’s +$9,12, Tuesday’s -$0.27 and Monday’s +$1.38);
  • Biostage (BSTG +$0.39 – pumped);
  • Chinook Therapeutics (KDNY +$0.36 after Wednesday’s -$0.12);
  • Precigen (PGEN +$0.10 after Wednesday’s -$0.04 and Tuesday’s -$0.24);
  • Bellicum Pharmaceuticals (BLCM +$0.05 after Wednesday’s -$0.19 and Tuesday’s +$0.28);
  • Pluristem (PSTI =$0.04 after Wednesday’s -$0.11);
  • MiMedx (MDXG +$0.01 after Wednesday’s -$0.10 and Tuesday’s +$0.27);
  • Solid Biosciences (SLDB +$0.01 after Wednesday’s -$0.02);
  • Applied Genetic Technologies (AGTC +$0.01);

Thursday’s (10 of 23) decliners:

  • Intellia Therapeutics (NTLA -$3.99 after Wednesday’s -$3.86, Tuesday’s +$4.28 and Monday’s +$8.75);
  • CRISPR Therapeutics (CRSP -$3.90 after Wednesday’s -$0.66, Tuesday’s +$1.44 and Monday’s +$7.80);
  • Alnylam Pharmaceuticals (ALNY -$2.53 after Wednesday’s +$3.02 and Tuesday’s +$3.50);
  • Editas Medicine (EDIT -$1.72 after Wednesday’s +$0.87, Tuesday’s -$0.64 and Monday’s +$4.98);
  • Fate Therapeutics (FATE -$1.69 after Wednesday’s +$1.41, Tuesday’s -$0.74 and Monday’s +$5.26);
  • Vericel (VCEL -$1.14 after Wednesday’s +$1.06, Tuesday’s +$0.20 and Monday’s+$2.31),
  • Sage Therapeutics (SAGE -$0.30 after Tuesday’s +$0.31);
  • Ionis Pharmaceuticals (IONS -$0.67 after Wednesday’s -$0.44, Tuesday’s +$0.95 and Monday’s -$0.23);
  • uniQure NV (QURE -$0.37 after Wednesday’s +$0.65);
  • Regenxbio (RGNX -$0.37 after Wednesday’s -$0.06, Tuesday’s -$0.13 and Monday’s +$2.13);

Closing – 2 –Athersys (ATHX), ReNeuron (RENE.L) and 1 -Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB closed down -0.69% and XBI closed down -0.45%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was up +2.05 points or =12.21% at 18.84

Upside volume:

  • Thursday:  3 out of the 9-upside had higher than the 3-month average volume;

Downside volume:

  • Thursday: 2 out of the 23-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: price versus percentage …

  • Thursday’s percentage (%) of the 9-upside were +0.07% (MDXG) to +17.65% (BSTG) while the 23-downside -0.18% (RARE) to -4.65% (CLBS);

 

August, the second month of Q3/21:

Thursday closed negative with 9 advancers, 23 decliners, 2 flats and 1 acquired

Wednesday closed positive with 20 advancers, 13 decliners, 1 flat and 1 acquired

Tuesday closed positive with 21 advancers, 12 decliners, 1 flat and 1 acquired

Monday (8/23) closed positive with 32 advancers, 1 decliner, 1 flat and 1 acquired

 

The BOTTOM LINE: What changes ... it was due!

As I had stated, “Investor conviction and any trust is being challenged even as the sector rises and falls, I … still believe a … “conflagration” is coming” – it seems to be started …

Reiterating, being overbought sets-up another partial “BUYING/SELLING “condition”.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started.

Q2 reporting season has essentially run its course; although a few remain with my questions of WHY so late …?

A tool that hasn’t resonated … guidance is one factor of the sector.

I am keeping an eye on “runways” … as 2024 seems to be timing factor for most.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.